Marker Therapeutics, Inc.
MRKR · XNASCIK 1094038fmd_0D5T0TG8PW8ANHAKNN8BSRWMRVManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2000 to Jun 30, 2026, 76 periods
| Line item | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | – | 0 | 0 | 0 | 1 | 1 | 4 | 3 | 7 | 4 |
| Net investment income | – | – | – | – | – | – | – | – | – | – |
| Research and development | 4 | 5 | 8 | 13 | 19 | 28 | 12 | 10 | 13 | 12 |
| Total operating expenses | 8 | 12 | 148 | 23 | 29 | 41 | 23 | 18 | 18 | 16 |
| Operating income | (8) | (11) | (148) | (23) | (29) | (39) | (20) | (15) | (11) | (13) |
| Non-interest expense | – | – | – | – | – | – | – | – | – | – |
| Interest expense | 0 | – | – | – | – | – | – | – | – | – |
| Interest and investment income | – | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 1 |
| Income before taxes | – | – | – | – | – | – | (20) | (14) | (11) | (12) |
| Income tax expense | 0 | 0 | 0 | – | – | – | – | 0 | 0 | (0) |
| Net income from continuing operations | – | – | – | – | – | – | (20) | (14) | (11) | (12) |
| Net income | (2) | (11) | (148) | (21) | (29) | (42) | (30) | (8) | (11) | (12) |